| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8338489 | PIERRE FABRE DERMA | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(5 years from now) | |
| US8987262 | PIERRE FABRE DERMA | Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
Oct, 2028
(5 years from now) | |
Hemangeol is owned by Pierre Fabre Derma.
Hemangeol contains Propranolol Hydrochloride.
Hemangeol has a total of 2 drug patents out of which 0 drug patents have expired.
Hemangeol was authorised for market use on 14 March, 2014.
Hemangeol is available in solution;oral dosage forms.
Hemangeol can be used as method to treat infantile hemangioma, method to treat hemangioma..
The generics of Hemangeol are possible to be released after 16 October, 2028.
Drugs and Companies using PROPRANOLOL HYDROCHLORIDE ingredient
Market Authorisation Date: 14 March, 2014
Treatment: Method to treat hemangioma.; Method to treat infantile hemangioma
Dosage: SOLUTION;ORAL
HEMANGEOL family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic